

SEMINARIOS EXTRAORDINARIO IRYCIS 2024

Vascular targeting of biotherapeutics for precise clinical interventions: not a panacea, yet a multipotent strategy

Vladimir R. Muzykantov

University of Pennsylvania

30 SEPTIEMBRE 2024 09:15h

Aula Maxi Lozano (Planta 7 Dcha) y on line (Zoom)

Vladimir Muzykantov (MD from First Moscow Medical School, 1980 and Ph.D. in Biochemistry from Russian National Cardiology Research Center, 1985), joined the University of Pennsylvania (PENN) as a Research Associate in the Perelman School of Medicine in 1993. He became a Tenured Professor of Pharmacology, with secondary appointment in Medicine and Vice-Chair of the Department of Systems Pharmacology and Translational Therapeutics. In 2010 he established the PENN Center for Targeted Therapeutics and Translational Nanomedicine (CT3N), which he directs. He also serves as the Scientific Leader of the Targeting Core and Theme in the PENN Institute for RNA Innovation established in 2023 (Dr. Drew Weismann, Founding Director).

Dr. Muzykantov published ~300 papers, has ~25 US Patents and about 50 submitted patent applications. Honors include: AHA Established Investigator (1996), AHA Bugher Stroke Award (2000), Chair of Transatlantic Airway Conference on Targeting Molecular Signatures in Lungs (Luzerne, 2009), Gordon Conference on Drug Carriers (2014). He also was inducted as an inaugural endowed Founders Professor of Nanoparticle Research at PENN.

His research focuses on drug delivery by red blood cells and endothelial targeting for treatment inflammation, thrombosis and ischemia in the lungs, heart and brain.